Bristol-Myers Squibb (BMY) has successfully completed its tender offer to acquire all outstanding shares of RayzeBio, Inc. for $62.50 per share in cash, amounting to approximately $4.1 billion. The offer, which expired on February 22, 2024, saw approximately 86% of RayzeBio's shares being validly tendered and not withdrawn. With the minimum condition for the tender offer satisfied, Bristol-Myers Squibb plans to promptly accept for payment all validly tendered shares on February 26, 2024. The acquisition will result in RayzeBio becoming a wholly owned subsidiary of Bristol-Myers Squibb, and its shares will be delisted from the Nasdaq Global Market. The merger is expected to be completed on the same day as the acceptance of the shares, without the need for a vote from RayzeBio's stockholders. Following the merger, Bristol-Myers Squibb intends to terminate the registration of RayzeBio's shares under the Exchange Act and suspend all of its reporting obligations as soon as practicable.

Bristol-Myers Squibb (BMY) has successfully completed its tender offer to acquire all outstanding shares of RayzeBio, Inc. for $62.50 per share in cash, amounting to approximately $4.1 billion. The offer, which expired on February 22, 2024, saw approximately 86% of RayzeBio's shares being validly tendered and not withdrawn. With the minimum condition for the tender offer satisfied, Bristol-Myers Squibb plans to promptly accept for payment all validly tendered shares on February 26, 2024. The acquisition will result in RayzeBio becoming a wholly owned subsidiary of Bristol-Myers Squibb, and its shares will be delisted from the Nasdaq Global Market. The merger is expected to be completed on the same day as the acceptance of the shares, without the need for a vote from RayzeBio's stockholders. Following the merger, Bristol-Myers Squibb intends to terminate the registration of RayzeBio's shares under the Exchange Act and suspend all of its reporting obligations as soon as practicable.